Deciphering the Molecular Basis of Melatonin Protective E ects on Breast Cells Treated with Doxorubicin: TWIST1 a Transcription Factor Involved in EMT and Metastasis, a Novel Target of Melatonin by Menéndez-Menéndez, Javier et al.
cancers
Article
Deciphering the Molecular Basis of Melatonin
Protective Effects on Breast Cells Treated with
Doxorubicin: TWIST1 a Transcription Factor Involved
in EMT and Metastasis, a Novel Target of Melatonin
Javier Menéndez-Menéndez 1 , Francisco Hermida-Prado 2,3,† , Rocío Granda-Díaz 2,3,†,
Alicia González 1, Juana María García-Pedrero 2,3 , Nagore Del-Río-Ibisate 2,3,
Alicia González-González 1, Samuel Cos 1, Carolina Alonso-González 1,*
and Carlos Martínez-Campa 1,*
1 Department of Physiology and Pharmacology, School of Medicine, University of Cantabria and Instituto de
Investigación Valdecilla (IDIVAL), 39011 Santander, Spain
2 Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación
Sanitaria del Principado de Asturias, 33011 Oviedo, Spain
3 Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain
* Correspondence: alonsogc@unican.es (C.A.-G.); martinezcm@unican.es (C.M.-C.)
† These authors equally contributed to this work.
Received: 30 April 2019; Accepted: 16 July 2019; Published: 19 July 2019


Abstract: Melatonin mitigates cancer initiation, progression and metastasis through inhibition of
both the synthesis of estrogens and the transcriptional activity of the estradiol-ER (Estrogen receptor)
complex in the estrogen-dependent breast cancer cell line MCF-7. Moreover, melatonin improves
the sensitivity of MCF-7 to chemotherapeutic agents and protects against their side effects. It has
been described that melatonin potentiates the anti-proliferative effects of doxorubicin; however, the
molecular changes involving gene expression and the activation/inhibition of intracellular signaling
pathways remain largely unknown. Here we found that melatonin enhanced the anti-proliferative
effect of doxorubicin in MCF-7 but not in MDA-MB-231 cells. Strikingly, doxorubicin treatment
induced cell migration and invasion, and melatonin effectively counteracted these effects in MCF-7
but not in estrogen-independent MDA-MB-231 cells. Importantly, we describe for the first time the
ability of melatonin to downregulate TWIST1 (Twist-related protein 1) in estrogen-dependent but
not in estrogen-independent breast cancer cells. Combined with doxorubicin, melatonin inhibited
the activation of p70S6K and modulated the expression of breast cancer, angiogenesis and clock
genes. Moreover, melatonin regulates the levels of TWIST1-related microRNAs, such as miR-10a,
miR-10b and miR-34a. Since TWIST1 plays a pivotal role in the epithelial to mesenchymal transition,
acquisition of metastatic phenotype and angiogenesis, our results suggest that inhibition of TWIST1
by melatonin might be a crucial mechanism of overcoming resistance and improving the oncostatic
potential of doxorubicin in estrogen-dependent breast cancer cells.
Keywords: melatonin; breast cancer; doxorubicin; chemotherapy; MCF-7 cells; TWIST1; p70S6K;
miR-10b
1. Introduction
Melatonin is an indolamine mainly secreted by the pineal gland during the night. It is a
multitasking molecule acting through various mechanisms (e.g., G-protein coupled membrane receptors,
interactions with orphan receptors or cytosolic molecules such as calmodulin), thereby playing multiple
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different roles as an antioxidant, immunomodulatory, endocrine regulatory molecule, circadian rhythm
synchronizer or anticancer agent controlling cell physiology [1–3]. Melatonin prevents cancer at the
initiation, tumor progression and metastatic dissemination [4,5]. In particular, the oncostatic actions
of melatonin have been largely described in hormone-dependent tumors, either when administered
alone or in combination with chemotherapeutic agents [6–8].
In breast cancer, the pineal hormone controls the transcriptional activity of the estradiol-estrogen
receptor complex, therefore behaving as a selective estrogen receptor modulator (SERM), and also
diminishes the production of estrogens through the regulation of the enzymes involved in estrogen
activation/inactivation, thus behaving as a selective estrogen enzyme modulator (SEEM) [9–11].
Melatonin has been tested in combination with different molecules and, as such, beneficial effects
have been demonstrated in preclinical studies [12], in vivo animal models [13,14] and in vitro cellular
models [15].
Melatonin sensitizes the estrogen-dependent breast cancer cell line MCF-7 to doxorubicin by
increasing its intracellular concentration, probably through inhibition of the P-glycoprotein [16].
Conversely, disruption of nocturnal melatonin driven by light-at-night in a model of MCF-7 cancer
xenografts grown in nude rats induces doxorubicin resistance that involves inhibition of phospho-AKT
activation. Importantly, melatonin acts dually as a tumor inhibitor and a circadian regulatory molecule,
thereby contributing to re-establish the sensitivity of breast tumors to doxorubicin, probably by
suppression of the Warburg effect (related to phospho-activation of AKT) and by inhibition of various
transcription factors such as STAT3 and NF-kB and proliferation and survival pathways including the
EGF and ERK families [17]. In both MCF-7 cells and rats bearing ER-responsive mammary tumors,
melatonin cooperates with doxorubicin resulting in lighter tumor weights, increased apoptosis, higher
expression of E-cadherin and higher survival rate, therefore indicating that melatonin potentiates
tumor sensitivity to doxorubicin [18,19].
However, the molecular basis of the protective role of melatonin and the impact on doxorubicin
response of breast cancer cells still largely remain to be elucidated. This prompted us to perform a
thorough analysis to decipher the functional role of melatonin on doxorubicin-treated breast cancer
cells and to identify the molecular mechanisms and signaling pathways involved in the regulation
by melatonin. We found that melatonin enhanced the anti-proliferative effect of doxorubicin and
counteracted the stimulatory effect of the anthracycline on cell migration and invasion in MCF-7 cells.
The pineal hormone inhibited activation of the Akt and p70S6 kinases and modulated multiple changes
in the expression of cancer, angiogenesis and clock genes. Importantly, we describe for the first time
the ability of melatonin to counteract the stimulatory effect of doxorubicin on TWIST1 (Twist-related
protein 1) expression and protein levels in estrogen-dependent but not in estrogen-independent breast
cancer cells. TWIST1 is involved in epithelial to mesenchymal transition and cancer metastasis and its
up-regulation correlates to poor survival [20–22].
Finally, we found that melatonin produced a significant regulation of several TWIST1-related
miRNAs which expression was altered by doxorubicin. Among them, melatonin was able to revert the
stimulatory effect of doxorubicin on the expression of miR-10b, known to be induced by TWIST1, thus
contributing to the acquisition of the metastatic phenotype and stimulation of angiogenesis [23,24].
Our results revealed that melatonin modulated multiple changes induced by doxorubicin, and
we found, for the first time, that melatonin counteracted the stimulatory effect of doxorubicin on the
expression of TWIST1 in breast cancer cells.
2. Results
2.1. Effects of Melatonin and Doxorubicin on the Proliferation of MCF-7 and MDA-MB-231 Cells
We first investigated the ability of melatonin to modulate the anti-proliferative effects of
doxorubicin, by using two different breast cancer cell lines: the hormone-dependent MCF-7 and the
hormone-independent MDA-MB-231.
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As expected, doxorubicin inhibited the proliferation of MCF-7 cells in a dose dependent manner
(Figure 1A). We next tested the effect of the addition of physiological doses of melatonin (1 nM) to cell
cultures treated with doxorubicin ranging from 10 to 1 nM. After 3 days of treatment, the proliferation
of MCF-7 cells decreased at doxorubicin concentrations of 5 and 10 nM. Lower concentrations of
doxorubicin had no effect on cell proliferation. Co-treatment with a physiological dose of melatonin
(1 nM) led to a significant further decrease in cell proliferation compared to cells treated with doxorubicin
alone (Figure 1B). However, in the triple-negative breast cancer cell line MDA-MB-231, co-treatment
with melatonin (1 nM) did not significantly alter the inhibitory effect of doxorucibin at any of the (even
high) doses tested (Figure 1C).
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Figure 1. Effects of doxorubicin (D) and elatonin ( ) on the proliferation of breast cancer cells. Cell
proliferation was measured by the MTT [3(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide]
method after 3 days of incubation with the different treatments specified below. (A) MCF-7 cells were
seeded into 96-well plates in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10%
FBS and treated with vehicle (control) or doxorubicin (ranging from 1 µM to 0.1 nM). (B) MCF-7
cells were seeded into 96-multiwell plates in DMEM supplemented with 10% FBS and treated with
doxorubicin (10 nM or 1 nM) alone or in combination with melatonin (1 nM) and incubated at 37 ◦C
for 3 days. Cell proliferation was measured by the MTT method. (C) MDA-MB-231 cells were seeded
into 96-multiwell plates in DMEM supplemented with 10% FBS and treated with doxorubicin (ranging
from 1 mM to 10 nM) alone or in combination with melatonin (1 nM). a, p < 0.001 vs. C; b, p < 0.05 vs.
C; c, p < 0.01 vs. D (10 nM); d, p < 0.01 vs. D (1 nM).
2.2. Effects of Melatonin and Doxorubicin on Cell Migration and Invasion in MDA-MB-231 and MCF-7 Cells
We next investigated the effects of doxorubicin and melatonin on the migratory capacity of MCF-7
and MDA-MB-231 cells by using wound-healing assays. As shown in Figure 2A,B, doxorubicin
treatment did not alter cell migration in MCF-7 cells, whereas melatonin significantly decreased cell
migration either alone or in combination with doxorubicin. In marked contrast, neither doxorubicin
nor melatonin had any effect on the migratory capacity of MDA-MB-231 cells (Figure 2C,D). When the
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invasive potential was tested, we found that doxorubicin enhanced the invasive potential of MCF-7
cells, whereas addition of melatonin counteracted this stimulatory effect (Figure 2G,H). In contrast, the
invasive potential of MDA-MB-231 was not altered by doxorubicin, and melatonin treatment did not
have any significant effect (Figure 2E,F).
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Figure 2. Effect of melatonin and doxorubicin on migration and on the invasive potential of MCF-7
and MDA-MB-231 cells. A, C Effects of melatonin (1 nM) and doxorubicin (1 µM) on MCF-7 (A) or
MDA-MB-231 (C) cell migration analyzed through the wound healing assay. Quantification of MCF-7
(B) or MDA-MB-231 (D) cell migration was expressed as mean± SEM. Representative microphotographs
of initial and after 24 h are shown. (E,G) Effects of melatonin (1 nM) and doxorubicin (1 µM) on MCF-7
(E) or MDA-MB-231 (G) invasive potential. Representative images from the 3D invasion assays of cell
spheroids embedded into a collagen matrix at initial (t = 0 h) and final time (t = 24 h) for the different
treatments are shown. (F,H) Graphs represent the quantification of the invasive area of MDA-MB-231
(F) or MCF-7 (H) cells at the indicated times. Data was expressed as mean ± SEM. A, C: Scale bar:
500 µm; E, G: Scale bar: 100 µm.
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2.3. Effects of Doxorubicin and Melatonin on the Expression of Cancer-Related Genes
We used the human breast cancer RT2 Profiler PCR Array to assess the expression changes in
MCF-7 cells upon treatment with doxorubicin (1 µM) either alone or combined with a physiological
dose of melatonin (1 nM). The RT2 Profiler PCR Array allows the simultaneous analysis of 84 genes
involved in various different key processes for breast cancer biology, such as angiogenesis, cell adhesion,
proteases, breast cancer classification markers, signal transduction, cell cycle, transcription factors,
apoptosis, DNA damage and repair. As shown in Table 1, doxorubicin alone upregulated the expression
of 27 genes and downregulated 17 genes.
Table 1. The table summarizes the distribution of breast cancer gene categories induced or repressed in
MCF-7 cells treated with doxorubicin (1 µM), doxorubicin plus melatonin (1 nM) or melatonin (1 nM)
for 6 h. Pathway-focused gene expression profiling was performed using the Human Breast Cancer
RT2 Profiler PCR Array. The number of up and downregulated genes in each category is indicated.
Breast Cancer Array
D vs. C D + M vs. D M vs. C
Up Down Up Down Up Down
Angiogenesis, cell adhesion
and proteases 5 3 2 1 0 2
Breast cancer classification
markers 2 1 1 4 1 5
Signal transduction 8 3 3 5 3 6
Cell cycle 5 1 0 7 4 3
Apoptosis and DNA
damage and repair 7 2 1 6 7 3
Transcription factors 0 7 2 3 2 3
D: Doxorubicin (1 µM), M: Melatonin (1 nM), C: control.
When doxorubicin was combined with melatonin, only nine genes were upregulated and the
number of downregulated genes increased to 26 (Table 1). Sixteen genes were selected for further
validation by performing specific real time RT-PCR analysis, establishing as selection criteria an
expression level change of at least 1.5-fold either with doxorubicin alone or in combination with
melatonin compared to vehicle-treated (control) cells. Thus, we were able to confirm (Figure 3A)
that doxorubicin (1 µM) significantly induced the expression levels of PTEN (phosphatase and tensin
homolog), COP1 (constitutive photomorphogenic 1) and CDKN1A (cyclin-dependent kinase inhibitor
1A). These three genes are known to act as tumor supressors in breast cancer, and their mutations can
cause chemoresistance [25–27]. Combination with melatonin (1 nM) further enhanced the anthracyclin
stimulatory effect. Importantly, melatonin counteracted the stimulatory effect of doxorubicin over the
expression of NME1 (a supressor or metastasis in breast carcinoma) [28]; MUC1 (a p53 supressor) [29];
SNAI2 (involved in invasion and EMT) [30]; BIRC5 (involved in doxorubicin resistance) [31]; and
TWIST1 (elevated in invasive breast cancer and involved in EMT [32,33] (Figure 3A).
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In some other cases, melatonin did not significantly change the expression levels of d xorubicin
inducers (BAX2, TP53). BAX2 and TP53 are largely described as apoptosis inducers [34]. Finally, the
pi eal hormone further enhanced the inhibition of gene expression induced by doxorubicin, as in the
case of XBP1 (a promoter of tumor invasion) [35]; WEE1 (involved in checkpoint progression) [36];
GATA3 (highly expressed in estrogen depe dent breast c ncers) [37]; PGR, that usually is overexpressed
in estroge positive breast carcino as [38] and BCL-2, a pro-survival protein whose targeting enhaces
vulnerability to therapy in ER-positive breast cancer [39]. The expression of the oncogene c-MYC [40]
was slightly downregulated by doxorubicin an dramatically inhibited by melatonin co-treatment
(Figure 3A).
he effect f combined treatm nt with dox rubicin and melatonin on gene expression was also
tested in the triple negative hormone-independent MDA-MB-231 cell line. The expression of TWIST1
and CDKN1A genes were prioritized for analysis, since the expression levels of these two genes were
found to dramatically change and be highly modulated by melatonin in MCF-7 cells. An increase on the
expression of CDKN1A was obtained after treatment with the anthracyclin; however, the expression of
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TWIST1 was not stimulated by doxorubicin in this cell line. The addition of melatonin and doxorubicin
together seem to cooperate to reach an additive effect on TWIST1 inhibition in MDA-MB-231, although
the inhibition reached after addition of melatonin is not as (Figure 3B).
2.4. TWIST1 Protein Levels Are Upregulated by Doxorubicin and Inhibited by Melatonin in MCF-7 Cells
As shown in Figure 3A, doxorubicin treatment induced a potent stimulation of TWIST1 expression
whereas co-treatment with melatonin counteracts this effect. For this reason, the protein levels of
TWIST1 were determined by confocal microscopy and immunoblotting. As seen in Figure 4A, TWIST1
protein expression increased upon treatment with doxorubicin; however, melatonin alone or combined
with doxorubicin decreased TWIST1 levels. We also tested the levels of ERα (Estrogen Receptor alpha),
since it is known that: melatonin downregulates ER in MCF-7 cells [41], doxorubicin upregulates
ER [42], and high levels of TWIST1 correlate with low levels of ER [43]. We found that the levels of
ERα were also downregulated by melatonin (Figure 4B). Therefore, analogous regulation of TWIST1
expression by doxorubicin and melatonin was observed at both mRNA and protein levels in MCF-7 cells,
which seem to be associated to ER expression (the whole western blots are available in supplementry
data, Figure S1; the quantification of the density of the bands can be seen in supplementary data,
Figure S3).
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Figure 4. (A) TWIST1 detection by immunofluorescence (IF). MCF-7 cells treated for 12 h with
doxorubicin (1 µM) and/or melatonin (1 nM) were fixed with formaldehyde and analyzed by IF
microscopy after staining with anti-TWIST1 antibody and DAPI (4′6-diamidino-2-phenylindole).
(B) Western blotting detection of TWIST1 and ERα in MCF-7 cells treated for 12 h with doxorubicin
(1 µM) and/or melatonin (1 nM). B-actin was used as loading control. Scale bar: 15 µm.
2.5. TWIST1 Gene Expression Is Regulated by Co-Culture of MCF-7 with Adipocytes
Adipocytes induce EMT in breast cancer cells, and TWIST1 upregulation among other factors.
On this basis, we examined whether adipocytes may induce the expression of TWIST1 in breast cancer
cells. The expression levels of CDKN1A gene were stimulated by adipocytes co-culture, potentiated by
doxorubicin and further increased by melatonin (Figure 5A). Co-culture of MCF-7 cells with adipocytes
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increased the expresion levels of the TWIST1 gene, and doxorubicin treatment further enhanced
TWIST1 levels. Co-treatment with melatonin diminished doxorubicin-induced expression of TWIST1
(Figure 5B).Cancers 2019, 11, x 8 of 26 
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Figure 5. Effects of doxorubicin and/or melatonin on CDKN1A and TWIST1 mRNA expression in MCF-7
cells co-cultured with mature adipocytes. Confluent human breast pre-adipocytes were differentiated
in adipocyte differentiation media. MCF-7 cells and differentiated adipocytes were co-cultured as
described in Materials and Methods, in the presence or absence of melatonin (1 nM) and/or doxorubicin
(1 µM) or vehicle (ethanol at a final concentration lower than 0.0001%). Control MCF-7 cells were grown
in the absence of adipocytes (column designated as MCF-7). After 24 h, total RNA was isolated from
MCF-7 cells, reverse transcribed and cDNAs were used for analysis of (A) CDKN1A and (B) TWIST1
mRNA expression by real time RT-PCR. All data are expressed as fold change relative to control cells
(mean ± SEM) from three independent experiments. a, p < 0.001 vs. A; b, p < 0.001 vs. C; c, p < 0.001
vs. D.
2.6. Effects of Doxorubicin and Melatonin on the Expression of Angiogenesis-Related Genes
We used the human angiogenesis RT2 Profiler PCR Array, to determine the gene expression
changes in MCF-7 cells upon treatment with doxorubicin (1 µM) either alone or in combination with
melatonin (1 nM). The angiogenesis RT2 Profiler PCR Array allows the simultaneous analysis of
84 genes involved in different processes linked to angiogenesis.
Doxorubicin alone upregulated the expression of 16 genes and downregulated eight genes
involved in different aspects of angiogenesis (e.g., cell adhesion regulation, matrix degradation or
growth factors) (Table 2). When both compounds were combined, the number of upregulated genes
was reduced to five, whereas 14 genes were downregulated. To further validate these data, eight genes
were selected (>1.5-fold change) and specifically analyzed by real time RT-PCR. Doxorubicin (1 µM)
was found to significantly stimulate the expression of PLG (plasminogen, downregulated by Twist1
inhibitors [44]; ANGPT2 (involved in breast cancer metastasis in brain) [45]; IGF-1 (a stimulator of
TWIST1) [46] and GLI1 (activated upon TWIST1 activation) [47]. Co-treatment with melatonin (1 nM)
blocked, at least partially, the stimulatory effect of the anthracyclin (Figure 6). The expression of VEGFA
(inducer of angiogenesis) [48] and AKT1 (inducer of TWIST1 activation) [49] was also significantly
reduced by combined treatment with doxorubicin and melatonin, while SERPINE1 expression was
unaffected by melatonin. Finally, the expression of the protease inhibitor TIMP2 was independent of
doxorubicin, but induced by melatonin (Figure 6).
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Table 2. The table summarizes the number of angiogenesis related genes which expression was induced
or repressed in MCF-7 cells treated with doxorubicin (1 µM), doxorubicin plus melatonin (1 nM) or
melatonin (1 nM) for 6 h. Genes were grouped as “adhesion molecules”, “proteases, inhibitors and
matrix proteins”, “cytokines and other factors” and “growth factors and receptors”. Pathway-focused
gene expression profiling was performed using the Human Angiogenesis RT2 Profiler PCR Array.
Angiogenesis Array
D vs. C D + M vs. D M vs. C
Up Down Up Down Up Down
Adhesion molecules 4 0 0 2 0 1
Proteases, inhibitors and matrix proteins 4 2 1 5 2 1
Cytokines and other factors 0 3 1 3 0 0
Growth factors and receptors 8 3 3 4 2 0
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2.7. Effects of Doxorubicin and Melatonin on the Expression of Clock Genes
Since the inactivation of CLOCK genes seems to be a mechanism involved in breast cancer risk [50],
we next assessed the effect of doxorubicin and melatonin on the expression of nine genes components
of the circadian clock system. Doxorubicin alone enhanced the transcription of six genes and melatonin
alone stimulated the expression of seven genes. The combination of both compounds remarkably
enhanced the expression of CRY1, CRY2, CLOCK, NPas2, BMAL1, BMAL2 and PER2. Only TIMELESS
expression was enhanced by doxorubicin whereas the stimulatory effect of the anthracycline was
partially counteracted by melatonin. PER3 expression was independent of doxorubicin and stimulated
by the presence of melatonin (Figure 7).
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Figure 7. Expression of CLOCK genes. CLOCK genes expression changes upon treatment with
doxorubicin (1 µM) and/or melatonin (1 nM) in MCF-7 cells. The following clock genes were selected for
analysis by specific RT-PCR: CRY1, CRY2, CLOCK, NPas2, BMAL1, BMAL2, PER2, TIMELESS and PER3.
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2.8. Combination of Melatonin and Doxorubicin on Kinase Intracellular Regulators
Next, we i vestig ed the effect of treatment with doxor bicin and melatonin of MCF-7 cells
on the activation/inactivation status of protein kinases by phosphorylation. This was accomplished
by using the Proteome ProfilerTM Array (R&D Systems, Minneapolis, MN, USA) to test the level of
phosphorylation of multiple protein kinases involved in different intracellular signaling pathways.
As shown in Figure 8A, doxorubicin induced the phosphorylation levels of p70S6 Kinase and this
effect was counteracted by co-treatment with melatonin. The level of p70S6 Kinase phosphorylation
relative to vehicle-treated control cells is represented in Figure 8B. The state of phosphorylation of
Akt (S473) and mTOR (S2448) (as upstream regulators of p70S6 kinase) and the ribosomal protein
S6 (S240) (as downstream target) were analyzed by western-blot. Melatonin alone reduced p-mTOR
and both total and p-Akt levels. The levels of p-Akt (Ser 473) and total Akt were lower in MCF-7
cells treated with doxorubicin plus melatonin in comparison with cells treated only with doxorubicin
(Figure 8C). The levels of p-S6 also decreased by melatonin treatment either alone or administered
with doxorubicin (Figure 8D). (The whole western blots are available in supplementry data, Figure S2;
Quantification of the density of the bands is available in supplementary data, Figures S4 and S5).
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Figure 8. State of phosphorylation of protein kinases. (A) Representative images of phospho-kinase
array blots assayed with protein extracts from MCF-7 cells, indicative the state of phosphorylation of
multiple kinases was assayed using the Proteome ProfilerTM Array and protein extracts fromMCF-7
cells treated for 6 h with dox rubicin (1 µM) and/or melatonin (1 M). The w ite oval remarks the dots
corresp nding to p70S6K levels. (B) The intensity of the signal of the dots corresponding to p70S6K
was quantified by densitometry and exp essed r lative to th control. (C) Wes ern blotting detecti n of
phosphorylated mTOR (S2448), total Akt and phosphorylated Akt (S473) in MCF-7 cells treated for 6 h
with doxorubicin (1 µM) and/or melatonin (1 nM). (D) Western blotting detection of S6 phosphorylation
(S240/S244) in MCF-7 cells treated for 6 h with doxorubicin (1 µM) and/or melatonin (1 nM).
2.9. Doxorubicin and Melatonin Modulate the Expression of miR-34a, miR-29a, miR-31, miR-10a, miR145 and
miR-10b in MCF-7 Cells
M croRNAs can function either as oncogenes or tumor supressors by regulating intracellular
signaling pathways [51]. Therefore, we decided to test the effect of doxorubicin and melatonin on the
expression of various miRNAs involved in epithelial to mesenchimal transition (EMT), cell growth,
migration, invasion, stem cell expansion and breast cancer progression, in correlation or not with
TWIST1. As shown in Figure 9, the expression of miR-34a was stimulated by doxorubicin and further
increased by melatonin co-treatment. miR-10b levels were also robustly induced by doxorubicin,
although completely reduced by melatonin co-treatment. Contrasting this, miR-29a expression and
miR-31 levels diminished by doxorubicin and melatonin co-treatment. The expression of miR-145,
stimulated by doxorubicin, was not altered by melatonin co-treatment. The anthracyclin induced the
expression of miR-10a, and melatonin significantly reduced this effect.
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levels ere analyzed in MCF-7 cells treated with doxorubicin alone (1 µM) and/or melatonin (1 nM) or
vehicle (ethanol at a final concentration lower than 0.0001%). All data are expressed as fold change
relative to control cells ( ean ± SEM) from three independent experiments. a, p < 0.001 vs. C; b,
p < 0.001 vs. D; c, p < 0.01 vs. C.
2.10. TWIST1 Blockade Abolishes the Stimulatory Effect of Doxorubicin on the Expression of miR-10b, miR-10a
and VEGFA
We next investigated the effect of knocking down TWIST1 in MCF-7 cells. For this purpose, MCF-7
cells were transfected with either siCONTROL or siTWIST1, and expression of miR-10b, miR-10a and
VEGFA was determined. As seen in Figure 10, the blockade of TWIST1 completely abolished the strong
induction of miR-10b, and also significantly diminished the induction of miR-10a by doxorubicin. In
addition, the expression levels of PLG, BIRC5 and VEGFA were significantly induced by doxorubicin
in siControl-transfected MCF-7 cells and dramatically reduced by melatonin cotreatment; however,
the expression changes observed upon doxorrubicin and combination treatment with melatonin were
completely abolished in siTWIST1-transfected cells. These data indicate that these expression changes
caused by treatment with doxorrubicin and melatonin are at least partially mediated by TWIST1.
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3. Discussion
The American Cancer Societ r rts t t ore than 70% of breast cancers are, at their initial
stages, hormone-dependent [52], meaning that their growth is promoted by estrogens. When the tumor
spreads out the breast, chemotherapy is a therapeutic option. Anthracyclines such as doxorubicin are
amongst the most common drugs used for adjuvant and neoadjuvant chemotherapy. Doxorubicin
binds to DNA in an intercalation process forming a stable complex [53]. Chemotherapy treatments
provoke undesirable severe side effects and development of acquired chemoresistance, involving a
variety of molecular events still not fully elucidated [54]. Thus, the use of adjuvant compounds might
help to overcome resistance, to diminish side effects, and to improve drug tolerance. Although many
of the gene expression and post-translational modifications triggered by chemotherapeutic drugs
have been characterized [7,8,55], there are many molecular modifications triggered in tumor cells in
response to chemotherapy remaining largely unknown.
Melatonin behaves as a protective agent against doxorubicin-induced toxicity [56,57], enhancing
apoptosis and cytotoxicity in cancer cells [19,58,59]. In rats, melatonin sensitizes mammary tumors
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to doxorubicin [18]; disruption of melatonin nocturnal production lead to a complete loss of tumor
sensitivity to doxorubicin [17]. Yet most of the molecular mechanisms triggered by doxorubicin and
modulated by melatonin remain unknown. As we have previously done for docetaxel [15], the aim of
this work was to deepen into the knowledge of the molecular mechanisms triggered by doxorubicin
and modified by the combination of doxorubicin and melatonin in breast cancer cells.
First, we tested the effect of doxorubicin and melatonin on the proliferation, migration and invasion
of MCF-7 and MDA-MB-231 cells. Melatonin potentiated the inhibitory effect of the anthracycline on
MCF-7 proliferation, inhibited migration (independent of doxorubicin) and the invasive potential in
MCF-7 cells, counteracting the stimulatory effect of the anthracycline, but not in MDA-MB-231 cells,
indicating that the effectiveness of melatonin may be related to the estrogen receptor status.
When we examined the gene expression profile of breast cancer related genes in MCF-7 cells, we
found that melatonin modulated some of the changes induced by doxorubicin. We further analyzed
the expression of 16 genes by specific RT-PCR. In some cases, melatonin and doxorubicin cooperated
to stimulate gene expression: PTEN, a tumor suppressor gene whose mutations (particularly in breast
cancer) cause chemoresistance [25]. CDKN1A (p21), the tumor suppressor controlling cell cycle and
tumor progression, although, recently, it has been described that overexpression and an abnormal
subcellular localization of p21 might correlate with poor response to chemotherapy [26]. COP1, another
factor with a controversial effect in cancer, since it has been described both as involved in resistance to
doxorubicin in leukemia cells [60] and as a suppressor of breast cancer progression [27].
Not all the tumor suppressor genes were modulated by melatonin; thus, NME1, a suppressor of
metastasis in breast carcinoma [28], was stimulated by doxorubicin and melatonin had no effect on
its expression.
Melatonin significantly counteracted the stimulatory effect of doxorubicin on the expression of
some genes: MUC1, (a p53 repressor) overexpressed in cancer [29], SNAI2, involved in invasion and
epithelial to mesenchymal transition [30] and BIRC5, an inhibitor of apoptosis highly expressed in
doxorubicin-resistant cells [31]. The regulation of TWIST1 was the most striking result. TWIST1 is a
transcription factor involved in mesoderm development [61,62]. TWIST1 is re-expressed in cancer,
since it bypasses p53-induced growth arrest [63], is elevated in invasive breast cancer [32], involved
in EMT [20,21], and correlates with poor survival [22]. We found that treatment of MCF-7 cells with
doxorubicin resulted in a strong induction of TWIST1 expression and co-treatment with melatonin
completely abolished this effect. The protein levels of TWIST1 were increased in doxorubicin treated
cells and melatonin impaired this stimulatory effect. Our results suggest that doxorubicin has a dual
action: it kills cancer cells, but simultaneously induces TWIST1 expression leading to EMT of the
surviving cells. The effect of doxorubicin on TWIST1 in MCF-7 cells was not obtained in MDA-MB-231
cells, again suggesting a correlation between melatonin action and the estrogen receptor status.
TWIST1 induces angiogenesis in vivo [64,65]. This prompted us to examine the gene expression
profile of angiogenesis related genes in MCF-7 cells. Doxorubicin stimulated the expression of
plasminogen (PLG), downregulated by compounds able to supress the TWIST1-dependent EMT [44].
Angiopoietin 2 (ANGPT2) involved in blood-brain barrier disruption and breast cancer metastasis in
brain [45]. Insulin like growth factor 1 (IGF1) a positive regulator of TWIST1 [46]. GLI1 (GLI family
zinc finger 1), activated when the hedgehog signaling and TWIST1 are activated, leading to migration
and invasion [47,66]. Importantly, melatonin partially blocked the stimulatory effect of doxorubicin on
PLG, ANGPT2, IGF-1 and GLI1 expression indicating an anti-angiogenic effect of the indoleamine.
Dim light exposure at night induces a circadian disruption of nocturnal melatonin, thus
contributing to doxorubicin resistance in breast cancer [17]. Since both melatonin and TWIST1
influence the expression of CLOCK-related genes [50,67,68], and inactivation of CLOCK, CRY1, BMAL1,
and PER1 has been proposed as a mechanism increasing breast cancer risk in shift workers [69], we
next studied the effect of doxorubicin in the expression of CLOCK genes in MCF-7 cells. Doxorubicin
stimulated CRY1, CRY2, CLOCK, BMAL1, BMAL2 and PER2 and melatonin significantly enhanced this
stimulatory effect. The only exception was TIMELESS, induced by doxorubicin and downregulated
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when melatonin is included in the treatment. This might be another important finding of this work,
since TIMELESS activates MYC, enhances ERα-mediated transactivation and contributes to tamoxifen
resistance [70,71].
Moreover, we found that melatonin reduces the levels of VEGFA. This growth factor is
upregulated by TWIST1, thus inducing angiogenesis in human umbilical vein endothelial cells [48],
result in agreement with previous work [72]. AKT1 was also significantly downregulated by
melatonin, as previously described [49,73,74]. In chemoresistant ovarian cancer cells, inhibition
of Akt phosphorylation, resulted in p70S6K inactivation and TWIST1 downregulation [75]. Therefore,
we focused our attention on the intracellular pathways triggered by protein kinases phosphorylation.
In a proteome profiler assay, we found that doxorubicin treatment induced a modest effect of melatonin
on Akt phosphorylation at Ser473. Phosphorylation of Akt correlates with poor prognosis and has
been found in MCF-7 cells but not in MDA-MB-231 [76,77]. Suppression of PTEN activates the
Akt/mTOR/p70S6K signaling and decreases sensitivity of MCF-7 cells to doxorubicin [78]. p-Akt
phosphorylates TWIST1 thus contributing to EMT and breast cancer metastasis [49]. In our hands,
melatonin downregulates p-mTOR and both total and p-Akt. However, we did not observe significant
changes in the levels of p-mTOR after treatment with doxorubicin or co-treatment with melatonin; the
modest inhibition of p-Akt in the cells treated simultaneously with both compounds suggests that
TWIST1 activation by doxorubicin might respond to other signaling pathways apart from Akt/mTOR.
We also observed an increase in the phosphorylation of P70S6K in response to doxorubicin. In head and
neck squamous cell carcinoma, activation of the S6 pathway has been correlated with EMT induction
and metastasis [79], and poor prognosis and tamoxifen resistance in breast cancer [80]. Interestingly,
our results showed that the phosphorylation of S6 induced by doxorubicin is inhibited by melatonin,
in parallel with a decrease in the levels of ERα. We tested ERα levels in parallel to TWIST levels, since
it has been previously described that melatonin downregulates ER in MCF-7 cells [41]. Doxorubicin
upregulates ER [42] and cell lines with high levels of TWIST1 have low levels of ER, being an increase of
TWIST1 levels a mechanism that might contribute to the generation of hormone-resistant ER-negative
breast cancer [43]. In our model, melatonin treatment decreased the levels of both proteins.
We next determined the expression of TWIST1 in MCF-7 cells co-cultured with adipocytes.
Adipocytes induce EMT in breast cancer cells by increasing, among some other factors, the expression
of TWIST1 [81,82]. Since transcriptional activation of the CDKN1A promoter by p53 is significantly
repressed by induction of TWIST1 [83], we tested whether adipocytes can induce the expression
of TWIST1 in MCF-7 cells. Indeed, co-culturing MCF-7 cells with adipocytes, even in absence
of any treatment, increased the expresion of TWIST1. This effect was enhanced by doxorubicin.
Co-treatment with melatonin abolished the stimulatory action of doxorubicin over TWIST1 expression.
The expression of CDKN1A was also stimulated by the presence of adipocytes in the co-cultures and
was upregulated by doxorubicin. In this case, cotreatment with doxorubicin plus melatonin further
increased the levels of CDKN1A. Therefore, adipocytes promote breast cancer cells adquisition of a
more aggressive phenotype and doxorubicin treatment contributes to stimulate the EMT processes,
whereas melatonin, at physiological concentrations, protects against TWIST1-mediated EMT.
MicroRNAs have been implicated in a wide range of intracellular signaling pathways [84].
Concerning carcinogenesis, they can act as oncogenes or tumor supressor genes [51]. In the last set of
experiments of this work, we tested the expression of some microRNAs known to play different roles
in cancer, directly or indirectly related to TWIST1.
MicroRNA-34a protects against breast cancer proliferation, invasion and metastasis by directly
targeting TWIST1 [85–87]. In MCF-7 cells, doxorubicin stimulates the expression of miR-34a, perhaps
a mechanism trying to compensate TWIST1 induction. Importantly, melatonin treatment further
stimulated the expression of miR-34a. MicroRNA-29a has been involved in MCF-7 cell proliferation and
invasion dependent on the IGF pathway [88]. Downregulation of miR-29a correlates with p21 and p53
upregulation, leading cancer cells to apoptosis [89]. We found that cells treated with both doxorubicin
plus melatonin showed lower levels of miR-29a, what might be another protective mechanism against
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malignity. The role of miR-31 in breast cancer is controversial. Whilst some reports conclude thart
miR-31 inhibits invasion and metastasis in breast cancer cell line models [90], other authors claim that
miR-31 promote cell proliferation and metastasis [91]. In our hands, miR-31 levels are downregulated
by doxorubicin and co-treatment with melatonin further inhibited miR-31 expression.
MicroRNA-10a is an inhibitor of breast cancer progression, promoting apoptosis in MCF-7 cells,
via PI3K/Akt/mTOR. Upregulation of miR-10a also suppresses the activation of p70S6K [92]. Our
results showed that, although melatonin alone has a stimulatory effect on its expression, is not able to
enhance the modest induction of miR-10a in response to doxorubicin, suggesting that miR-10a does
not play a crucial role in TWIST1 induction by doxorubicin.
miR-145 provides a link between p70S6K to TWIST1. P70S6K prevents the maturation of miR-145,
and consequently, TWIST1 is upregulated, leading to metastasis [93]. Reactivation of miR145 supressed
migration and invasion of breast cancer cells [94]. In our model, the expression of miR-145 is stimulated
by doxorubicin and melatonin, however, the addition of both compounds simultaneously does not
further increase miR-145 levels.
We also tested the levels of miR-10b, described as an oncogenic microRNA involved in tumor
invasion, angiogenesis, cellular motility and metastasis [95,96]. TWIST1 induces miR-10b [23,96]
promoting breast cancer bone metastasis [97]. We found that doxorubicin strongly stimulates miR-10b
expression, whereas melatonin concomitantly added with the anthracyclin abolishes this stimulatory
effect. Thus, the inhibition of miR-10b, probably a consequence of TWIST inhibition, might be another
mechanism participating in the protective role of melatonin on doxorubicin breast cancer treated cells.
When we were preparing our manuscript, Chao et al. reported that melatonin supresses lung cancer
metastasis, preventing EMT by downregulating TWIST1, which agrees with our results, indicating that
TWIST1 might be a novel target of melatonin in different cancer types [98].
Importantly, the blockade of TWIST1 expression by siRNA technology completely abolished the
induction of miR-10b, PLG and BIRC5 by doxorubicin, allows a higher effect of melatonin on miR-10a
expression and partially impaired the stimulatory action of doxorubicin on VEGFA expression. These
data indicate that TWIST could be involved in the expression changes of these genes and miRNAs
observed upon treatment with doxorrubicin and melatonin.
4. Materials and Methods
4.1. Cell Lines and Culture Conditions
Human breast cancer cell lines MCF-7 (hormone-dependent, ERα-positive) and MDA-MB-231
(hormone-independent, triple negative) were acquired from the American Tissue Culture Collection
(Rockville, MD, USA). They were maintained as monolayer cultures in 75 cm2 plastic culture flasks in
Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma-Aldrich, Madrid, Spain) supplemented with
10% fetal bovine serum (FBS) (PAA Laboratories, Pasching, Austria), 2 mM L-Glutamine (GIBCO,
Langley, OK, USA), penicillin (20 units/mL) and streptomycin (20 µg/mL) (Sigma-Aldrich, Madrid,
Spain) at 37 ◦C in a humid atmosphere containing 5% CO2.
Breast preadipocytes (ZenBio, RTP, Durham, NC, USA) were plated in six-well TC plates (Corning,
Lowell, MA, USA), and propagated in preadipocyte media (ZenBio, RTP, Durham, NC, USA) at 37 ◦C
in a humidified atmosphere of 5% CO2.
4.2. Co-Culture of Breast Adipocytes and MCF-7 Cells as an In Vitro Breast Cancer Model
Confluent pre-adipocytes were propagated in adipocyte differentiation media (ZenBio, RTP,
Durham, NC, USA) for 7 days. Following the differentiation media, the resulting adipocytes were
propagated in DMEM:F12 (GIBCO®, Invitrogen, Carlsbad, CA, USA) containing 1% PSF (GIBCO®,
Invitrogen), 10%fetal bovine serum (Sigma, St. Louis, MO, USA), and 5 ng/mL insulin (GIBCO®,
Invitrogen) for 7 days.
Mature adipocytes and MCF-7 cells were co-cultured together using Falcon 24-multiwell plates
and Falcon cell culture inserts. First, mature adipocytes (12 × 103 cells/well) were cultured in the
Cancers 2019, 11, 1011 17 of 27
upper chamber in DMEM supplemented with 10% FBS for 24 h. At this time, inserts containing
MCF-7 cells (5 × 103 cells/well) were seeded in the lower chamber and co-cultured with or without
mature adipocytes (12 × 103 cells/well) in fresh DMEM medium containing melatonin (1 nM) and/or
doxorubicin (1 µM) or vehicle (ethanol at a final concentration lower than 0.0001%). After 24 h, total
RNA was isolated from MCF-7 cells and purified with the Nucleospin RNA II kit (Macherey-Nagel,
GmbH & Co. Düren, Germany), and used for cDNA synthesis.
4.3. Cell Proliferation Assay
MDA-MB-231 and MCF-7 cells were cultured for 3 days in media containing melatonin (1 nM)
and/or doxorubicin (ranging from 0.1 nM to 1 µM) or vehicle (ethanol at a final concentration lower
than 0.0001%). Cell proliferation was measured by the MTT [3(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide] method [99], reading absorbance at 570 nm in a microplate reader (Labsystems
Multiskan RC 351, Vienna, VA, USA). MTT was obtained from Molecular Probes Inc (Molecular Probes,
Eugene, OR, USA). Each result represents the media ± S.E.M of at least three independent experiments
and data are presented as percentage of control untreated cells.
4.4. Cell Migration Assay: Wound Healing Assay
MDA-MB-231 and MCF-7 cells were seeded into 6-well plates (Life Sciences, Tewksbury, MA,
USA) and cultured for 24 h in DMEM supplemented with 10% FBS (csFBS) to reach full confluence. A
line of cells was scraped away in each plate using a pipette tip. Media were replaced by fresh ones
containing melatonin (1 nM) and/or doxorubicin (1 µM) or vehicle (ethanol at a final concentration
lower than 0.0001%). At least four randomly selected views along the scraped line in each plate were
photographed using an ORCA R2 camera (Hamamatsu Photonics, Massy Cedex, France) attached to a
microscope set Nikon Ti (Werfen Group, Barcelona, Spain) at 10×magnification. Microphotographs
were taken every ten minutes during the course of the experiment, which was terminated after 24 h.
Initial and final wound sizes were determined using the Nis Elements v.3.8 software (Nikon, Tokyo,
Japan) and the difference between the two was used to determine migration distance as follows: initial
wound size minus final wound size divided by two. Each assay was performed at least three times.
4.5. Three-Dimensional Spheroid Invasion Assays
MDA-MB-231 and MCF-7 cells were suspended in DMEM medium plus 5% methyl cellulose
(Sigma-Aldrich, Madrid, Spain) at 80,000 cells/mL. Cell spheroids were subsequently formed by serial
pippeting of 25 µL into a non-adhesive petri dish (2000 cells/spheroid) and incubated in an inverted
position for 18 h. Next, each spheroid was transferred to an individual well of 96-well plate and
embedded into a volume of 110 µL of 2.3 mg/mL bovine collagen type I matrix (PureCol, San Diego,
CA, USA) from advanced Biomatrix, and filled with 100 µL of complete media.
Collective cell invasion was monitored using a Zeiss Cell Observer Live Imaging microscope
coupled with a CO2 and temperature maintenance system. Time-lapse images were acquired every
20 min during 24 h using a Zeiss AxioCam MRc camera (Carl Zeiss, Sliedrecht, The Netherlands).
The area of each individual spheroid was measured using ImageJ Fiji analysis program (version 1.50i,
Bethesda, MD, USA). The invasive area was determined by calculating the difference between the final
area (at each represented time) and the initial area (t = 0 h), and data were normalized to the control
(vehicle-treated) cells. Each assay was performed at least three times using quadruplicates.
4.6. RNA Isolation and cDNA Synthesis
Total RNA was isolated from MCF-7 and MDA-MB-231 cells and purified with the Nucleospin
RNA II kit (Macherey-Nagel, GmbH & Co. Düren, Germany) following the manufacturer’s
instructions. The concentration and purity of RNA was quantified by measuring the absorbance
in a spectrophotometer (Nanodrop, Thermofisher, Control Técnica, Boadilla del Monte, Spain). The
absorbance ratio A260 nm/A280 nm was always > 1.9. For cDNA synthesis, 0.5 µg of total RNA was
used as template using the RT2 First Strand Kit (Qiagen, Germantown, MD, USA), following the
manufacturer´s instructions. First, the genomic DNA was eliminated by incubating the samples 5 min
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at 42 ◦C. After mixing with the reverse-transcription mix, the samples were incubated for exactly 15
min at 42 ◦C in a final volume of 20 µL. The reaction was stopped by incubating at 95 ◦C for 5 min. 91
µL of RNA-free water was added to each reaction and samples were kept on ice until proceeding with
the real-time PCR protocol.
4.7. RT2 ProfilerTM PCR Array
Pathway-focused gene expression profiling was performed using a 96-well human breast
cancer PCR array (RT2 Profiler PCR array-PAHS-131ZA, Human Breast Cancer PCR Array,
Qiagen, Germantown, MD, USA) and a 96-well human angiogenesis PCR array (RT2 Profiler PCR
array-PAHS-024ZA, Human Angiogenesis PCR Array, Qiagen, Germantown, MD, USA). In these
arrays, each well contains all the components required and designed to generate single, gene-specific
amplicons, testing the expression of 84 genes related to breast cancer pathways or to angiogenesis,
5 housekeeping genes and controls for data normalization, genomic DNA contamination detection,
RNA sample quality and general PCR performance.
Briefly, MCF-7 were treated for 6 h with doxorubicin (1 µM) alone or in combination with 1 nM
melatonin and/or vehicle (ethanol at a final concentration lower than 0.0001%). RNA was extracted and
reverse transcribed as explained in the Section 4.6. The cDNA template was mixed with the appropriate
amount of RT2 SYBR Green qPCR Mastermix (Qiagen GmbH, Hilden, Germany), aliquoted 25 µL to
each well of the same plate, and then the real-time PCR cycling program was performed in an MX3005P
(Agilent, Santa Clara, CA, USA) following the manufacturer’s instructions.
Cycling conditions were: 1 cycle at 95 ◦C for 10 min followed by 40 cycles using the following
temperature profile: 95 ◦C for 30 sec (denaturation) and 60 ◦C for 60 sec (annealing/extension).
Dissociation curves were performed to verify that only a single product was amplified. The Ct data for
each gene were analyzed using the Qiagen RT2 profiler PCR array data analysis software. Data are
represented as fold-regulation between the experimental groups and the control cells.
4.8. Measurement of Specific mRNA Gene Expression
Analysis of specific mRNA gene expression was carried out by RT-PCR after incubation of cells for
6 h with doxorubicin (1 µM) and/or melatonin (1 nM), or vehicle (ethanol at a final concentration lower
than 0.0001%). Total cellular RNA was isolated, reverse transcribed and the RT-PCRs were performed
using the same temperature profile described in Section 4.7.
Reactions were run in triplicate and melting curves were performed to verify that only a single
product was amplified. Each result represents the media of three to five independent experiments and
data are presented as fold-change between the experimental groups and the control cells. The primers
used for amplification (Sigma Genosys Ltd., Cambridge, UK) are listed in Table 3.







































4.9. Real-Time RT-PCR Data Analysis
For the primers used there were no differences between transcription efficiencies, and the
fold-change in each sample was calculated by the 2−∆∆Ct method [100]. The fractional cycle at which
the amount of amplified target becomes significant (Ct) was automatically calculated by the PCR
program. The relative expression of β-actin was used to normalize gene expression.
4.10. Quantification of miRNAs Expression
Total RNA, including the small RNA fraction, was extracted from MCF-7 cells using TRIzol reagent
(Invitrogen). TaqMan® MicroRNA Reverse Transcription Kit (Life Technologies, Carlsbad, CA, USA)
was used for the RT step. Corresponding TaqMan® Human MicroRNA Assays (Life Technologies,
Carlsbad, CA, USA) were used to determine the copy number of miR-10a, miR-10b, miR-29a, miR-31,
miR-34a, miR-133a and miR-145. MiRNAs levels were normalized to the expression levels of RNU6B,
which was measured in parallel for each specific miRNA determination. Each sample was assayed in
triplicate and a negative control was included in each experiment. Cycling conditions were an initial
cycle of 95 ◦C for 10 min, followed by 50 cycles of 95 ◦C for 15 s, and 60 ◦C for 90 s, performed in an
MX3005P (Agilent, Santa Clara, CA, USA) thermocycler.
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4.11. Phosphokinase Screening
MCF-7 cells were initially seeded into 6-well plates at a density of 5 × 105 cells per well in DMEM
supplemented with 10% FBS and incubated at 37 ◦C for 24 h to allow for cell attachment. Then,
media were replaced by fresh ones with 10% FBS and containing either doxorubicin alone (1 µL)
and/or melatonin (1 nM) or vehicle (ethanol at a final concentration lower than 0.0001%). After 6 h
of incubation, cells were washed with PBS, lysed and screened for phosphorylation of kinases with
the Proteome ProfilerTM Array (Human Phospho-kinase Array Kit, Catalog Number ARY003B, R&D
Systems, Minneapolis, MN, USA) according to manufacturer´s instructions.
4.12. Antibodies
Antibody against actin (A5441) was purchased from Sigma Aldrich (Madrid, Spain). Antibodies
against TWIST1 (2c1a, Cc-81417) and ER (F-10, Sc-8002) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Antibodies against phospho-S6 ribosomal protein (D68F8), Phospho-Akt
(Ser473) (92712), Akt (4691L) and phospho-mTOR (Ser2448) (D9C2) were purchased from Cell Signaling
(Danvers, MA, USA)
4.13. Western Blotting
MCF-7 cells were initially seeded into 6-well plates at a density of 5 × 105 cells per well in DMEM
supplemented with 10% FBS and incubated at 37 ◦C for 24 h to allow for cell attachment. Then,
media were replaced by fresh ones with 10% FBS and containing either doxorubicin alone (1 µM) or in
combination with melatonin (1 nM) and/or vehicle (ethanol at a final concentration lower than 0.0001%).
Samples for Western blotting were prepared by harvesting cells under appropriate conditions for
centrifugation, resuspending the pellet in SDS buffer, and boiling for 5 min. Equal amounts of protein
lysate were resolved by SDS-PAGE, transferred to polyvinylidene difluoride (PVDF) membrane and
blocked in a buffer containing 5% non-fat milk. Western blots were probed with various primary
antibodies listed above. The blots were stripped and re-probed with anti-β-actin antibody (Sigma,
St. Louis, MO, USA) to evaluate loading. Images were acquired with the Odyssey infrared imaging
system and analyzed by the software program as specified in the Odyssey software manual.
4.14. Immunofluorescence Staining
For immunofluorescence assays, MCF-7 cells were seeded onto glass coverslips in 6-well plates
and grown for 24 h. Then, media were replaced by fresh ones with 10% FBS and containing either
doxorubicin alone (1 µM) and/or melatonin (1 nM), or vehicle (ethanol at a final concentration lower
than 0.0001%). After 12 h, cells were washed with PBS, fixed in 4% formaldehyde solution for 30 min
and then permeabilized with 0.2% Triton X-100/PBS for 15 min (twice). Coverslips were incubated with
anti-TWIST1 primary antibodies overnight at 4 ◦C, followed by 1 h incubation with fluorescence-tagged
secondary antibody at room temperature, and then stained with DAPI for 5 min. Finally, coverslips
were observed, and cell images were captured at 40×magnification with an LSM-510 laser scanning
microscope (Carl Zeiss Inc., Sliedrecht, The Netherlands) fluorescence microscope.
4.15. Small Interfering RNA (siRNA)
Small interfering RNA (siRNA) technology was used to knock down TWIST1
expression. A mixture of four siRNA (ON-TARGETplus SMARTpool TWIST1
siRNA) were purchased from Dharmacon (Lafayette, CO, USA). The target sequences
were: 5′-UGAGCAACAGCGAGGAAGA-3′, 5′-GGAGUCCGCAGUCUUACGA-3′,
5′-GCAAAUAGAUCCGGUGUCU-3′ and 5′-AAUCAGAGGAACUAUAAGA-3′. A non-silencing
siRNA siGENOME RISC-Free Control was used as negative control. MCF-7 cells were transfected with
pooled siRNA using Lipofectamine 2000 (Invitrogen). The group designed as Mock corresponded to
MCF-7 cells going through the transfection process without addition of siRNA. After 72 h, cells were
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treated with doxorubicin and/or melatonin for 6 h and RNA was extracted using Trizol (Gibco). Gene
expression and miRNAs expression were determined by real time RT-PCR, as described in Sections 4.8
and 4.10.
4.16. Statistical Analysis
Statistical analyses were performed using GraphPad Prism software. The data are expressed as
the means ± standard errors of the mean (SEM). Statistical differences between groups were analyzed
using One-Way Analysis of Variance (ANOVA), followed by the Student-Newman-Keuls test. Results
were considered as statistically significant at p < 0.05.
5. Conclusions
In summary, this study has extensively contributed to deciphering multiple molecular changes
modulated by doxorubicin and melatonin treatment in breast cancer cells that include gene expression
changes, kinase activation and miRNAs expression. A model is proposed in Figure 11, indicating the
factors induced or inhibited by melatonin.Cancers 2019, 11, x 21 of 26 
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According to these original data, TWIST1 emerges as a central player in doxorubicin-treated
breast cancer cells, since some of the upstream regulators of TWIST1 (PTEN, Akt, IGF, p70S6K,
c-Myc, TIMELESS, miR-29a, miR-34a, miR145) and dowstream effectors (GLI1, Survivin, p21, Bcl-2,
Bax, VEGFa, SLUG1, Per1, Per2, miR-10b) have all been found altered upon doxorubicin treatment.
Importantly, melatonin may exert a protective role thereby modulating many of the undesirable
effects of this chemotherapeutic agent, preventing cell proliferation, migration, invasion and EMT in
ER-positive breast cancer cells.
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Figure S1: Western blot analysis of TWIST1, ER and actin, Figure S2: Western blot analysis of p-mTOR, Total
Akt, p-Akt and actin, Figure S3: Western Cuantification of the density of the bands included in Figure 4. It was
made by using the image proccessing package ImageJ Fiji, Figure S4: Western Cuantification of the density of the
bands included in Figure 8C. It was made by using the image proccessing package ImageJ Fiji, Figure S5: Western
Cuantification of the density of the bands included in Figure 8D. It was made by using the image proccessing
package ImageJ Fiji.
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